After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine. According to the approval letter,

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising concerns over future vaccine access. The US Food and Drug Administration (FDA) has given full approval to Novavax’s Covid-19 vaccine,